Falk Gastro Info 7/2015

Video

 

 

Video course abdominal ultrasound

Examination of the gallbladder under stressful conditions

 

Author: Prof. Dr. Christoph F. Dietrich, Caritas Krankenhaus Bad Mergentheim.

© 2015 Falk Foundation e.V., Freiburg. All rights reserved.

 

 

Please switch on your loudspeakers!

 

 

Link to Falk Mediacenter:

http://media.falkfoundation.de/index.php?id=138&L=1

 

Link to the video directly:

http://media.drfalkpharma.de/fileadmin/media/22_Gall_Examination_of_th_gallbladder_under_stressfull_conditions_ENG.mp4

 

Preview images:

 

580 x 350 pixels (with arrow)

http://www.drfalkpharma.de/fileadmin/media/newsletter/Logos/Sono_Clip22_580P.jpg

 

580 x 350 pixels (without arrow)

http://www.drfalkpharma.de/fileadmin/media/newsletter/Logos/Sono_Clip22_580.jpg

 

 

Bowel

 

 

Text:

Frederiksen MT et al, Inflamm Bowel Dis. 2014;20(10):1714–21

Patients with inflammatory bowel disease and loss of response towards infliximab due to anti-infliximab antibodies are prone to develop de novo anti-adalimumab antibodies following switch to adalimumab therapy.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#29059

 

 

Text:

Bonderup OK et al, Inflamm Bowel Dis. 2014;20(10):1702–7

This large population based study confirms that therapy with proton-pump inhibitors, non-steroidal anti-inflammatory drugs, statins, and selective serotonin reuptake inhibitors are associated with the diagnosis of microscopic colitis.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29060

 

 

Text:

Jess T et al, Clin Gastroenterol Hepatol. 2014;12(11):1793–1800.e1

In a meta-analysis, the authors did not find a significant protective effect of treatment with thiopurines on the risk of colorectal neoplasia in patients with inflammatory bowel disease.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29061

 

 

 


 

Liver
Biliary Tracts

 

 

 

 

Text:

Radcke S et al, Eur J Gastroenterol Hepatol. 2015;27(1):1–7

A systematic review shows that 10–20% of the general population have elevated liver enzymes, a finding that does not necessarily indicate severe liver disease.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29062

 

 

 

 

Text:

Fontaine H et al, Gut. 2015;64(1):139–46

In a recent trial, therapeutic DNA vaccination in chronic HBV infection did not prevent relapse after discontinuation of oral antiviral therapy.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29063

 

 

 

 

Text:

Kreisel W et al, Dig Liver Dis. 2015;47(2):144–50

Udenafil reduces portal pressure in patients with compensated liver cirrhosis without ascites by 20% without relevant systemic cardiovascular side effects.

 

 

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29064

 

 

 

 

 

 

 

 

 

 

 

 

Oesophagus

Stomach

Duodenum

 

 

Text:

Molina-Infante J et al, Aliment Pharmacol Ther. 2015;41(6):581–9

Empiric quadruple therapy (esomeprazole, amoxicillin, clarithromycin and metronidazol) achieved significantly higher cure rates of Helicobacter pylori infection compared to conventional triple therapy.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29065

 

 

Text:

Sengupta N et al, Am J Gastroenterol. 2015;110(2):328–35

Restarting anticoagulation at discharge after gastrointestinal bleeding was associated with fewer thromboembolic events without a significantly increased risk of recurrent gastrointestinal bleeding at 90 days.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29066

 

 

Text:

Khalaf N et al, Clin Gastroenterol Hepatol. 2014;12(11):1832–9.e6

The use of non-steroidal anti-inflammatory drugs is associated with a reduced risk of esophageal adenocarcinoma, but not of Barrett’s esophagus.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29067

 

 

Pancreas

 

 

Text:

Kochar B et al, Gastrointest Endosc. 2015;81(1):143–9.e9

According to this meta-analysis, the incidence of post-ERCP pancreatitis amounts to 9.7% of patients undergoing ERCP with a mortality rate of 0.7%. There were no major differences between high-risk patients and the general population.

 

Link:

http://www.drfalkpharma.de/index.php?L=1&id=20371#c29068

 

 

Current Falk literature:

 

 

NEW

The role of the liver in metabolic syndrome

Obesity – insulin resistance – NAFLD

Pathophysiology, clinical symptoms and treatment options

Authors: A. Canbay, J.P. Sowa, G. Gerken

(55 pages)

U15e

 

Picture:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/Titelblatt/U15e.jpg

 

PDF:

http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Diagnostik_und_Therapie/PDF/U15e_1-5_15.pdf

 

 

 

Order by email (Please replace text by your email address):

 

mailto:text?subject=FGI%27%2F2015:%20Ordering%20of%20brochure%20U15e&body=Please%20send%20the%20brochure%20to%20the%20following%20address:%0A%0A